|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 27, 2012 ) New York, NY -- Shares of Lpath Inc (LPTN) were moving on Monday as a key catalyst that had been expected to unfold for months finally did. The LPTN share price dropped to below the dollar mark earlier this year after the company announced that iSONEP trials would be halted due to a non-compliance issue with the FDA by the company's fill/finish contractor. There were no safety or other concerns regarding iSONEP itself, but the potential months-long trial halt created enough uncertainty in the minds of traders to spark enough of an exodus for shares to dip to below seventy cents from January's highs of well over a buck. It also didn't help, however, that a stock offering was announced right around the time of the trail halt.
VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, continues to follow these key developments and believes that with trials now resumed, LPTN could potentially challenge its previous 52-week highs over the short term, with higher gains possible as the trials mature, as described in an article posted today:
http://vfcsstockhouse.com/blog/article/-a-unique-technology-and-expected-catalyst-has-lpath-shares-on-the-move
A news release on Monday demonstrated that enrollment is back on track for the halted trials and shares initially reacted accordingly with a ten percent move higher. According to the release, Lpath will continue recruiting patients for its Nexus trial, measuring the effectiveness of iSONEP as a potential treatment for wet AMD. The first patient in the re-started trial is expected to be treated in mid-September and the news brought in volume of over double the daily norm.
With Lpath back in the clinical trial game for iSONEP, investors could again start making note of the company's potential as a leader in the field of lipid-based therapeutics. With the ImmuneY2 platform, Lpath's actual and potential pipeline products contain the ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to the spreading and growth of various diseases and inflammatory/auto-immune disorders. The market potential for this technology in treating a plethora of modern day illnesses and diseases, should it advance past the clinical stages, is huge, and Lpath with iSONEP and ASONEP - is first applying its technology to the treatment of Wet AMD and cancer, respectively. Both of these target markets alone hold multi-billion dollar potential.
Pfizer (PFE), a company already flush with cash and always on the prowl for 'pipelines of the future' as many big money makers come off patent, has already made a relatively significant investment in the future of the ImmuneY2 platform with an up-front payment of $14 million in a deal that could be worth nearly half a billion dollars in development, regulatory and commercial milestone payments, should the specified milestones be met. Along with the deal Pfizer also retains a 'first right of refusal' for ASONEP development, as well.
"We have been impressed by Lpath's innovative approach in targeting bioactive lipids with iSONEP and the potential opportunity to significantly add to current standards of treatment in retinal disease," noted Mikael Dolsten, president of Pfizer Worldwide Research and Development, at the time the deal was announced.
Such words from an official of a huge pharmaceutical player is validation enough of the potential of a developmental company's pipeline - as most big players do not jump into these partnership deals until a potential FDA approval is within sight - but the financial commitment validates the technology even further.
Follow these Lpath developments at VFCsStockHouse.com
Contact VFC's Stock House: vfc@vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
